Giant Centrifugal and Necrotizing Cutaneous Metastases of Melanoma

Meo, Nicola di; Nan, Katiuscia; Vichi, Silvia; Gatti, Alessandro; Trevisan, Giusto

doi:10.1177/1203475415620395

Cited by 1 publication

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The key feature is necrosis and ulceration of the skin tumors in the absence of therapy. In addition, albeit rare to date, cases suggestive of this diagnosis have been observed in patients with untreated solid tumors (such as melanoma, breast cancer, and Kaposi sarcoma) [7,[27][28][29][30][31][32][33][34][35][36][37][38][39].…”

Section: Spontaneous (Idiopathic) Cutaneous Tumor Lysis Syndromementioning

confidence: 99%

“…However, it remains unclear if some of these cases were accompanied by rapid tumor death, a key feature of cutaneous tumor lysis syndrome [7,[27][28][29][30][31][32][33][34][35][36][37][38][39]. Solid tumors: In addition to patients with Kaposi sarcoma, characteristics possibly compatible with solid tumor-associated spontaneous (idiopathic) cutaneous tumor lysis syndrome have also been reported in patients with other solid tumors (Table 4) [7,[35][36][37][38][39]. For example, a 79-year-old man with metastatic melanoma in whom the phenomenon was referred to as giant centrifugal and necrotizing cutaneous metastases of melanoma [35].…”

Section: Spontaneous (Idiopathic) Cutaneous Tumor Lysis Syndromementioning

confidence: 99%

“…Solid tumors: In addition to patients with Kaposi sarcoma, characteristics possibly compatible with solid tumor-associated spontaneous (idiopathic) cutaneous tumor lysis syndrome have also been reported in patients with other solid tumors (Table 4) [7,[35][36][37][38][39]. For example, a 79-year-old man with metastatic melanoma in whom the phenomenon was referred to as giant centrifugal and necrotizing cutaneous metastases of melanoma [35]. Another patient was a woman with metastatic breast cancer who concurrently presented with not only spontaneous (idiopathic) cutaneous tumor lysis syndrome but also spontaneous (idiopathic) systemic tumor lysis syndrome [39].…”

Section: Spontaneous (Idiopathic) Cutaneous Tumor Lysis Syndromementioning

confidence: 99%

See 2 more Smart Citations

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System

Cohen¹,

Prieto

Kurzrock

2021

Cureus

View full text Add to dashboard Cite

Tumor lysis syndrome, an oncological emergency, is characterized by laboratory parameters such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, as well as renal injury with an elevated creatinine. Tumor lysis syndrome is seen in patients with aggressive malignancies and high tumor burden. More frequently, it occurs in individuals with hematologic malignancies such as high-grade lymphomas (such as Burkitt lymphoma) and leukemia (such as acute lymphocytic leukemia). It also, albeit less commonly, can be seen in patients with widespread solid tumors that are rapidly proliferating and are markedly sensitivity to antineoplastic therapy. Tumor lysis syndrome is usually preceded by cancer-directed therapy; however, the syndrome can present spontaneously prior to the individual receiving malignancydirected treatment. We reported a man with metastatic salivary duct carcinoma who had cutaneous metastases that presented as carcinoma hemorrhagiectoides. Microscopic examination demonstrated that the metastatic tumor cells had infiltrated and replaced the entire dermis. After the patient received his first dose of antineoplastic therapy, he had an excellent response and the cutaneous metastases developed into ulcers; we hypothesize that most of the dermis, which had been replaced by tumor cells, disappeared as a result of the therapeutic response, and the overlying epidermis became necrotic and shed, leaving an ulcer. His dramatic response to treatment prompted us to propose a new classification of tumor lysis syndrome, which should include the systemic form of the condition as well as the new variant: cutaneous tumor lysis syndrome. We anticipate that, with improvement in targeted therapies, there may be an increase in therapyassociated cutaneous tumor lysis syndrome.

show abstract